Angeles Alvarez Secord, MD, MHSc, discusses the rationale behind the phase 1/2 BEHOLD-2 trial evaluating mocertatug rezetecan plus dostarlimab in endometrial cancer.
Bringing B7-H4 Antibody-Drug Conjugates to the Forefront of Gynecologic Cancers
The B7-H4–targeted ADC produced ORRs of 62% and 67% in patients with PROC and endometrial cancer, respectively, in the phase 1 BEHOLD-1 study.
Advertisement
Advertisement